Header Logo

Connection

Annette Langer-Gould to Male

Back to Details
This is a "connection" page, showing publications Annette Langer-Gould has written about Male.
Annette Langer-Gould
Connection Strength
1.756
Male
  1. Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul; 11(4):e200255.
    View in: PubMed
    Score: 0.090
  2. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections. Neurol Neuroimmunol Neuroinflamm. 2024 May; 11(3):e200211.
    View in: PubMed
    Score: 0.090
  3. Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023 Nov; 10(6).
    View in: PubMed
    Score: 0.087
  4. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. JAMA Netw Open. 2022 12 01; 5(12):e2248664.
    View in: PubMed
    Score: 0.082
  5. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022 05 03; 98(18):e1818-e1827.
    View in: PubMed
    Score: 0.079
  6. Reader Response: Leadership, Recognition Awards, and Publication by Men and Women in the American Academy of Neurology. Neurology. 2021 07 27; 97(4):200-201.
    View in: PubMed
    Score: 0.075
  7. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021 04; 8(4):938-943.
    View in: PubMed
    Score: 0.073
  8. Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2021 03; 8(2).
    View in: PubMed
    Score: 0.072
  9. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis. 2020 Oct; 99:291-297.
    View in: PubMed
    Score: 0.070
  10. Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. Neurology. 2020 04 07; 94(14):e1548-e1556.
    View in: PubMed
    Score: 0.068
  11. MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics. Nutrients. 2018 Feb 27; 10(3).
    View in: PubMed
    Score: 0.059
  12. Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis. Nutrients. 2018 Feb 07; 10(2).
    View in: PubMed
    Score: 0.059
  13. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study. Neurology. 2017 Sep 26; 89(13):1330-1337.
    View in: PubMed
    Score: 0.057
  14. Association between vaccines and neuroinflammation-reply. JAMA Neurol. 2015 May; 72(5):605.
    View in: PubMed
    Score: 0.048
  15. Place of birth,age of immigration,and disability in Hispanics with multiple sclerosis. Mult Scler Relat Disord. 2015 Jan; 4(1):25-30.
    View in: PubMed
    Score: 0.047
  16. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014 Dec; 71(12):1506-13.
    View in: PubMed
    Score: 0.047
  17. The incidence of clinically isolated syndrome in a multi-ethnic cohort. J Neurol. 2014 Jul; 261(7):1349-55.
    View in: PubMed
    Score: 0.045
  18. Spinal cord lesions and disability in Hispanics with multiple sclerosis. J Neurol. 2013 Nov; 260(11):2770-6.
    View in: PubMed
    Score: 0.043
  19. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013 May 07; 80(19):1734-9.
    View in: PubMed
    Score: 0.042
  20. Reply: To PMID 22633290. J Pediatr. 2013 May; 162(5):1084.
    View in: PubMed
    Score: 0.042
  21. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013 Feb 05; 80(6):548-52.
    View in: PubMed
    Score: 0.041
  22. Pediatric idiopathic intracranial hypertension and extreme childhood obesity. J Pediatr. 2012 Oct; 161(4):602-7.
    View in: PubMed
    Score: 0.039
  23. Vitamin D levels in Hispanics with multiple sclerosis. J Neurol. 2012 Dec; 259(12):2565-70.
    View in: PubMed
    Score: 0.039
  24. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011 Sep 20; 77(12):1143-8.
    View in: PubMed
    Score: 0.037
  25. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010 Jul; 16(7):855-61.
    View in: PubMed
    Score: 0.034
  26. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009 Jun; 29(2):104-6.
    View in: PubMed
    Score: 0.032
  27. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec; 63(12):1686-91.
    View in: PubMed
    Score: 0.027
  28. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28; 353(4):375-81.
    View in: PubMed
    Score: 0.024
  29. Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA Neurol. 2023 07 01; 80(7):693-701.
    View in: PubMed
    Score: 0.021
  30. Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis: evidence for a suppressive pregnancy-related serum factor. J Immunol. 2002 Jul 15; 169(2):1084-91.
    View in: PubMed
    Score: 0.020
  31. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021 12 01; 4(12):e2136697.
    View in: PubMed
    Score: 0.019
  32. Safety of potential breast milk exposure to IFN-ß or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
    View in: PubMed
    Score: 0.017
  33. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 07 02; 7(4).
    View in: PubMed
    Score: 0.017
  34. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 05; 87(5):688-699.
    View in: PubMed
    Score: 0.017
  35. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 02 01; 77(2):184-191.
    View in: PubMed
    Score: 0.017
  36. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019 03 05; 92(10):e1029-e1040.
    View in: PubMed
    Score: 0.016
  37. Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019 03 05; 92(10):e1016-e1028.
    View in: PubMed
    Score: 0.016
  38. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019 01; 15(1):e1007808.
    View in: PubMed
    Score: 0.016
  39. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012; 16(3):37-41.
    View in: PubMed
    Score: 0.010
  40. Health plan administrative records versus birth certificate records: quality of race and ethnicity information in children. BMC Health Serv Res. 2010 Nov 23; 10:316.
    View in: PubMed
    Score: 0.009
  41. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88.
    View in: PubMed
    Score: 0.007
  42. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2003 Nov-Dec; 24(10):1941-5.
    View in: PubMed
    Score: 0.005

© 2024 Kaiser Permanente